Twice Weekly Sulfamethoxazole/Trimethoprim for Pneumocystis jiroveci Pneumonia Prophylaxis in Lung Transplant Recipients.

ABSTRACT:

Background

Pneumocystis jiroveci pneumonia (PJP) prophylaxis is recommended indefinitely for lung transplant recipients (LTR). To mitigate the side effects of oral sulfamethoxazole-trimethoprim (SMX/TMP) in LTR, our center prescribes SMX/TMP single-strength (SS) twice weekly for PJP prophylaxis. To our knowledge, this regimen has not been evaluated in the literature. We sought to determine the incidence of PJP infection and SMX/TMP discontinuation in LTR taking this regimen.   METHODS: This retrospective review evaluated LTR first single or bilateral lung transplant at our center from June 1, 2014 to September 1, 2022. Data was obtained from the United Network of Organ Sharing Data Reports and chart review. The primary outcome was the incidence of PJP infection in LTR taking SMX/TM

SUBMITTER: Munroe C 

PROVIDER: S-EPMC12519929 | biostudies-literature | 2025 Sep-Oct

REPOSITORIES: biostudies-literature